Blood-based colon cancer screen shows promise in UW-Madison study

(University of Wisconsin-Madison) In a study published April 8, 2019, in the Proceedings of the National Academy of Sciences, a group of University of Wisconsin-Madison scientists has identified four blood-based fingerprints -- human protein markers -- associated with the pre-cancerous forms of colon cancer that are most likely to develop into disease.The scientists expect their findings will ultimately lead to a blood test for the cancer, adding a method to help increase screening rates while reducing overtreatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 22 June 2019Source: Chemico-Biological InteractionsAuthor(s): Chandra Kishore, Sandhya Sundaram, Devarajan KarunagaranAbstractTumor recurrence and metastasis decrease the survival rate of colorectal cancer (CRC) patients. Menadione reduces the numbers and incidences of 1,2-dimethylhydrazine induced colon tumors in mouse but the mechanism of anticancer activity of menadione in colorectal cancer is not very clear. Since Wnt signaling is constitutively active in CRC and it aggravates the epithelial mesenchymal transition (EMT), the regulation of EMT and Wnt signaling by menadione (vitamin K3...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Conditions:   Cancer, Breast;   Cancer of Colon;   Cancer of Rectum;   Cancer Intervention:   Device: Plan to Thrive smartphone application Sponsors:   Northwestern University;   Vignet, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: Randomized control trials and population-based studies do not demonstrate a definitive benefit for adjuvant chemotherapy (ACT) in stage II colon cancer (CC). Tumor sidedness and microsatellite instability (MSI) status may predict response to ACT, but previous studies have limited microsatellite data. We assessed the efficacy of ACT and possible interaction with MSI status and tumor sidedness in patients with resected stage II CC diagnosed between 2010 and 2013 using the National Cancer Database. Materials and Methods: Overall survival was evaluated with the Kaplan-Meier method and multivariate and propensi...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
ConclusionIFN-I induces STAT3 activation to activateGzmb expression to enhance CTL effector function to suppress tumor development. Human colorectal carcinoma may use down-regulation of IFNAR1 on CTLs to suppress CTL effector function to evade host cancer immunosurveillance.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Long noncoding RNA SNHG15 enhances the development of colorectal carcinoma via functioning as a ceRNA through miR-141/SIRT1/Wnt/β-catenin axis. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2536-2544 Authors: Sun X, Bai Y, Yang C, Hu S, Hou Z, Wang G Abstract Colon cancer, also known as colorectal carcinoma (CRC), remains to be one of the most mainsprings of cancer-produced deaths entire world. We planned to grab the role and possible biological cause of a long noncoding RNA, namely, small nucleolar RNA host gene 15 (SNHG15), in CRC. The mRNA level of SNHG15 in CRC tissues and cells was detected,...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
CDx Diagnostics is on a mission to provide clinicians with tests and tools to preempt cancer through enhanced detection of precancerous cellular changes. The Suffern, NY-based company accomplishes this goal with WATS3, a diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. MD+DI caught up with the company’s founder and CSO to discuss the evolution of the company and where it goes from here. MD+DI: Let’s talk a little bit about CDx D...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
Acromegaly results in a significantly increased morbidity and mortality due to cardiovascular and respiratory complications as well as malignancies arising mainly from the colon. Furthermore, an increased lifetime risk of malignant transformation of pre-malignant colonic lesions relates to a worse overall prognosis from colorectal cancer, which is currently considered a major disease related complication. In this review we provide some insight into colonic changes in this condition, summarise current knowledge and evidence on the use of colonoscopic screening in patients with acromegaly, and suggest a recommended screening protocol.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: The development of this novel dual FGTI overcomes a major hurdle in KRAS resistance, thwarting growth of patient-derived mutant KRAS-driven xenografts from pancreatic cancer patients, and as such it warrants further preclinical and clinical studies. PMID: 31227505 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsFuture studies aimed at improving FIT screening and subsequent colonoscopy rates need to address the unique needs of patients for effective and sustainable screening programs.Trial RegistrationNCT01946282
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
Prolyl hydroxylase 3 (PHD3) has initially been reported to hydroxylase hypoxia-inducible factor α (HIFα) and mediate HIFα degradation. More recent studies have shown that, in addition to HIFα, PHD3 has also other substrates. Moreover, pHD3 is believed to act as a tumor suppressor, but the underlying mechanism remains to be elucidated. Here, we demonstrate that PHD3 stabilizes p53 in a hydroxylase-independent manner. We found that PHD3 overexpression increases and PHD3 knockdown decreases p53 levels. Mechanistically, PHD3 bound MDM2 proto-oncogene (MDM2) and prevented MDM2 from interacting with p53, ...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Signal Transduction Source Type: research
More News: Academies | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Study | University of Wisconsin